25th Sep 2015 05:44
LONDON (Alliance News) - Irish pharmaceuticals company Shire PLC late on Thursday said a US court of appeals has upheld a previous judgement protecting certain patent claims on its Vyvanse attention-deficit hyperactivity disorder treatment which will keep generic version of the drug off the market until 2023.
FTSE 100-listed Shire said the Court of Appeals of the Federal Circuit upheld the summary judgement made by the US District Court for the District of New Jersey affirming the validity of its patents.
The lawsuit filed by Shire named all the known pharmaceutical manufacturers which had filed new drug applications with the US Food and Drug Administration with plans to launch a generic version of Vyvanse. This included Actavis LLC, Amneal Pharmaceuticals LLC, Mylan Pharmaceuticals Inc and Roxane Laboratories Inc. The suit also named the manufacturer and supplier of the generic versions, Johnson Matthey Inc, a unit of London-listed chemicals company Johnson Matthey PLC.
Shire said the ruling will prevent the defendants from launching generic version of Vyvanse until Shire's patents expire in 2023. It said the ruling may be subject to an appeal and the defendants may submit a petition with the US Supreme Court to overturn the ruling.
"We are extremely pleased that the Federal Circuit affirmed the District Court's ruling that the patents are valid, which further confirms that Shire has strong patents protecting Vyvanse," said Mark Enyedy, the interim general counsel at Shire.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
Shire